

Jarushka Naidoo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4057376/publications.pdf>

Version: 2024-02-01

108
papers

13,870
citations

53794

45
h-index

45317

90
g-index

111
all docs

111
docs citations

111
times ranked

17958
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	27.0	1,495
2	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	13.7	1,395
3	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	1.6	829
4	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
5	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	9.4	706
6	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	1.6	580
7	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	1.6	445
8	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	4.9	393
9	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	7.0	342
10	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC: an Update From the PACIFIC Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 860-867.	1.1	323
11	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.9	317
12	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	3.8	311
13	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
14	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	4.9	284
15	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1930-1939.	1.1	282
16	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.8	257
17	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	3.4	247
18	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	7.1	241

#	ARTICLE	IF	CITATIONS
19	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	27.8	234
20	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.8	230
21	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
22	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. <i>Cancer</i> , 2015, 121, 3212-3220.	4.1	160
23	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 99-111.	13.2	141
24	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 332-338.	0.9	140
25	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	1.6	138
26	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	1.6	135
27	Immune-related adverse events and the balancing act of immunotherapy. <i>Nature Communications</i> , 2022, 13, 392.	12.8	125
28	Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2014, 2, 127-132.	3.4	122
29	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	1.6	121
30	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 553-557.	3.4	119
31	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. <i>Cancer Immunology Research</i> , 2018, 6, 888-899.	3.4	118
32	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. <i>Clinical Lung Cancer</i> , 2016, 17, e121-e129.	2.6	116
33	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2019, 14, 494-502.	1.1	114
34	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
35	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4305-4315.	8.2	100
36	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e31-e43.	5.6	97

#	ARTICLE	IF	CITATIONS
37	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Nonâ€‘Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	7.0	90
38	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
39	Immuneâ€‘Related Adverse Events From Immune Checkpoint Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 242-251.	4.7	84
40	Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Nonâ€‘Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e470-e479.	2.6	80
41	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
42	Early Noninvasive Detection of Response to Targeted Therapy in Nonâ€‘Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1204-1213.	0.9	75
43	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. <i>Oncologist</i> , 2017, 22, 627-630.	3.7	74
44	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. <i>Lancet Oncology</i> , The, 2020, 21, e398-e404.	10.7	74
45	A Multidisciplinary Toxicity Team for Cancer Immunotherapyâ€‘Related Adverse Events. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 712-720.	4.9	71
46	Immune Checkpoint Blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 585-600.	2.2	70
47	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)â€‘related interstitial lung disease/pneumonitisâ€‘Focus on proactive monitoring, diagnosis, and management. <i>Cancer Treatment Reviews</i> , 2022, 106, 102378.	7.7	60
48	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
49	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
50	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	2.5	54
51	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Nonâ€‘Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e435-e444.	2.6	46
52	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
53	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Nonâ€‘Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.	1.1	42
54	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42

#	ARTICLE	IF	CITATIONS
55	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. <i>Journal of Oncology Practice</i> , 2019, 15, e825-e834.	2.5	37
56	Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1215-1221.	1.1	35
57	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
58	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	2.8	31
59	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. <i>Oncologist</i> , 2021, 26, e1822-e1832.	3.7	31
60	Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e169-e170.	2.6	24
61	Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014, 6, 195-209.	2.0	23
62	KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 155-178.	1.6	23
63	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. <i>Current Oncology Reports</i> , 2020, 22, 56.	4.0	23
64	Pneumonitis From Anti-PD-1/ PD-L1 Therapy. <i>Oncology</i> , 2017, 31, 739-46, 754.	0.5	23
65	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2021, 27, 2571-2583.	7.0	22
66	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
67	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. <i>Immunotherapy</i> , 2017, 9, 5-8.	2.0	20
68	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	1.0	19
69	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. <i>Cancer Treatment Reviews</i> , 2022, 104, 102350.	7.7	18
70	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. <i>PLoS ONE</i> , 2016, 11, e0146063.	2.5	17
71	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 46.	3.0	16
72	Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082.	4.1	15

#	ARTICLE	IF	CITATIONS
73	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
74	Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 467-472.	4.9	13
75	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 771-782.	2.1	12
76	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 2016, 102, 21-27.	2.0	11
77	Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877829.	3.2	11
78	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. Journal of Dermatological Treatment, 2022, 33, 1691-1695.	2.2	11
79	Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC.. Journal of Clinical Oncology, 2022, 40, 8541-8541.	1.6	11
80	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 2020, 1, 100074.	1.1	10
81	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2022, 71, 2405-2420.	4.2	10
82	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
83	A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.. Journal of Clinical Oncology, 2018, 36, 6538-6538.	1.6	9
84	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	1.7	9
85	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. Journal of Investigative Dermatology, 2022, 142, 2896-2908.e4.	0.7	9
86	Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer. Lung Cancer, 2020, 150, 249-251.	2.0	7
87	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer, 2022, 166, 84-93.	2.0	7
88	Information Visualization Platform for Postmarket Surveillance Decision Support. Drug Safety, 2020, 43, 905-915.	3.2	6
89	The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. Clinical Advances in Hematology and Oncology, 2017, 15, 615-625.	0.3	6
90	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4034-S4037.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. <i>Cancer Investigation</i> , 2021, 39, 789-796.	1.3	5
92	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100220.	1.1	4
93	Successful Treatment of Scar Pain with Scrambler Therapy. <i>Cureus</i> , 2019, 11, e5903.	0.5	4
94	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 123-131.	2.7	4
95	A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. <i>Oncologist</i> , 2020, 25, e1589-e1592.	3.7	3
96	Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2609-2609.	1.6	3
97	Lung cancer and family-centered concerns. <i>Supportive Care in Cancer</i> , 2020, 28, 497-505.	2.2	2
98	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 462-463.	2.9	2
99	Reply to M. Nishino et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1629-1630.	1.6	1
100	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2018, 129, 75-77.	8.2	1
101	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. <i>Npj Breast Cancer</i> , 2015, 1, .	5.2	0
102	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 44-45.	0.6	0
103	Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy. <i>Practical Radiation Oncology</i> , 2018, 8, e239-e248.	2.1	0
104	4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 73-73.	0.6	0
105	Immune-Related Adverse Events and Efficacyâ€”The More It Hurts, the Better It Works?â€”Reply. <i>JAMA Oncology</i> , 2021, 7, 945.	7.1	0
106	An Irish breast cancer survivorship study: Are we meeting our patients' needs?. <i>Journal of Clinical Oncology</i> , 2013, 31, e20687-e20687.	1.6	0
107	681â€”Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
108	An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis. <i>Current Oncology</i> , 2022, 29, 4342-4353.	2.2	0